-+ 0.00%
-+ 0.00%
-+ 0.00%

The reporter learned from the site of the 2025 Innovative Drug High Quality Development Conference held today that Eli Lilly's terpopeptide was added to the 2025 National Basic Medical Insurance Catalogue. It is reported that the indications for the inclusion of titerpotide in the medical insurance catalogue this time are indications for type 2 diabetes and obstructive sleep apnea. Eli Lilly said that in the next three years, the company will launch more than 20 new products and new indications in China.

Zhitongcaijing·12/07/2025 03:25:00
Listen to the news
The reporter learned from the site of the 2025 Innovative Drug High Quality Development Conference held today that Eli Lilly's terpopeptide was added to the 2025 National Basic Medical Insurance Catalogue. It is reported that the indications for the inclusion of titerpotide in the medical insurance catalogue this time are indications for type 2 diabetes and obstructive sleep apnea. Eli Lilly said that in the next three years, the company will launch more than 20 new products and new indications in China.